Targeting the insulin-like growth factor-1 receptor to overcome imatinib resistance in chronic myeloid leukemia
Abstract Patients with chronic myeloid leukemia (CML) frequently develop resistance to tyrosine kinase inhibitors such as imatinib. In this study, we explored the role of the insulin-like growth factor 1 (IGF-1) signaling pathway in CML and imatinib resistance. An analysis of IGF-1 gene expression u...
Saved in:
Main Authors: | Seiichi Okabe, Yuya Arai, Akihiko Gotoh |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-12-01
|
Series: | Discover Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s12672-024-01706-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01) -
Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01) -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Massimo Breccia, et al.
Published: (2011-05-01) -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01) -
Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development
by: Irina Badralexi, et al.
Published: (2024-12-01)